SS
DSGN icon

Steve Schonfeld’s Design Therapeutics DSGN Stock Holding History

Steve Schonfeld’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,100
Closed -$88.8K – 1888
2023
Q2 		$88.8K Buy
14,100
+700
+5% +$4.28K ﹤0.01% 1743
2023
Q1 		$77.3K Buy
+13,400
New +$100K ﹤0.01% 1731

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Steve Schonfeld's DSGN Position: Q3 2023 in Review

Steve Schonfeld sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 14,100 shares — an estimated $88.8K sold.

Steve Schonfeld first reported a position in DSGN in Q1 2023 and held it in 2 quarters. The position peaked at $88.8K in Q2 2023. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

  • Steve Schonfeld reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Steve Schonfeld sold 14,100 Design Therapeutics shares in Q3 2023, an estimated $88.8K.
  • Steve Schonfeld first reported a position in Design Therapeutics in Q1 2023 and held it in 2 quarters.
  • Steve Schonfeld's Design Therapeutics position peaked at $88.8K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.